Protocols for relapsed ALL, past and current

AALL1121         A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTEĀ® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
COG-AALLO1P2 (an outline on this site) completed II 1/03 to 12/05 bone marrow relapse, induction therapy
COG-AALLO2P2 (an outline on this site) active not specified 11/2004-present late EM relapse
COG-AALL0433 outline active (temp. closed 2008) III 2007-2011 intermediate risk: bone marrow relapse >36months after initial dx; combined BM and EM relapse >36 months; isolated EM relapse less than 18 months after initial dx
COG-ADVL04P2 outline active II 2005-present Early marrow relapse. Epratuzumab Alone and in Combination With Re-Induction Combination Chemotherapy in Pediatric Patients With Relapsed CD22-Positive ALL. Epratuzumab is anti-CD22 monoclonal antibody. This trial is Epratuzumab combined with the backbone therapy of AALL01P2.
AAML0523 outline active I/II 7/08-present 2nd or more marrow relapse. Study of Clofarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
ASCT0431 outline active III 2007 Late marrow relapse > 36 mos from diagnosis. Randomized Study of Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus and Methotrexate With or Without Sirolimus in Pediatric Patients With Intermediate-Risk or High-Risk Acute Lymphoblastic Leukemia in Second Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
St. Judes ALLR17 (a brief overview on this site) active II 2003-present covers all types of relapses
BFM ALL-REZ 2002 ALL-REZ BFM 2002 active Protocol for the Treatment of Children with Relapsed Acute Lymphoblastic Leukemia
POG-9411 outline completed II 1995-7 first marrow relapse regardless of time after dx, with or without EM relapse, or first EM relapse with M2 marrow; transplant vs aggressive chemotherapy
POG-9412 outline completed II 1996-2000 isolated CNS relapse, regardless of time after dx
CCG-1941 outline completed III 1995-7(?) bone marrow relapse while on frontline therapy or within a year of completion of frontline therapy
POG-9310 outline completed II 1993-4 bone marrow/EM/combined relapse; escalating rotational drug therapy
POG-9061 outline completed II, I 1990-3 isolated CNS relapse
BMTCTN-0501 outline active III 2006-present Single- vs double-unit umbilical cord blood transplantation; for relapsed ALL, high-risk ALL, and Myelodysplastic Syndromes
FHCRC-1629.00 outline active I, II 2005-present Fred Hutchinson: Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
UKALL R2 outline closed III 1995-2002 UK trial; Randomized Study of Unrelated Donor BMT vs Continuing Chemotherapy for Childhood Acute Lymphoblastic Leukemia in First Relapse
CCG-1951 outline closed III 1996- 2002 Study of Systemic Chemotherapy Combined with Local Therapy for Isolated Extramedullary Relapse of Acute Lymphoblastic Leukemia